Publication | Closed Access
First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung
732
Citations
20
References
2012
Year
Gefitinib failed to demonstrate superior OS compared with GP as first-line therapy for NSLAs.
| Year | Citations | |
|---|---|---|
Page 1
Page 1